#USA #West Lafayette #Improved Pharma #Ritonavir #MicroED

Publication of Ritonavir Form IV Crystal Structure

Improved Pharma has recently published a groundbreaking study in the journal Crystal Growth & Design detailing the crystal structure of Ritonavir Form IV. This significant research uses advanced micro-electron diffraction (MicroED) techniques to characterize the anhydrous polymorph, establishing vital thermodynamic relationships between this new form and previously known forms of Ritonavir. Understanding these relationships is essential in the pharmaceutical landscape, as polymorphism plays a critical role in drug formulations and stability.

Importance of Polymorphism in Pharmaceuticals

Ritonavir, an antiretroviral medication approved for the treatment of HIV, serves as a prime example of the challenges presented by polymorphism in drug development. The history of Ritonavir is notable; it was famously recalled in 1998 due to the unexpected appearance of a more stable polymorph, Form II, which interfered with the production of the original Form I. This case is emblematic of the complex nature of polymorphism in pharmaceutical compounds, as altering their structural forms can significantly impact their efficacy and safety.

The Journey to Ritonavir Form IV

In 2014, Form III was reported, but it wasn't until 2022 that it was fully characterized as a distinct polymorph. Coincidence brought together two research initiatives from AbbVie and a collaboration between Improved Pharma and Varda Space Industries, both of which led to the discovery of Form III through melt/cool crystallization. Building on this momentum, Improved Pharma’s latest study elucidates the crystal structure of Ritonavir Form IV using MicroED, showcasing the evolutionary progress in the characterization of Ritonavir polymorphs.

Advancements in Structural Analysis

The successful determination of the structure of Form IV was made possible through modern structural analytical techniques, including MicroED, which is capable of resolving structures of nanoparticles that are too small for conventional single-crystal X-ray diffraction. The critical partnership with Pierre Le Maguerès and the Rigaku team provided invaluable support and access to the Rigaku XtaLAB Synergy-ED instrument, which proved essential for tackling the intricate challenges posed by the nanocrystals involved.

Collaboration and Future Implications

The research exemplifies the collaborative spirit within the scientific community, with authors from Varda Space Industries contributing significantly to the project. Improved Pharma remains dedicated to advancing the understanding of complex solid-state relationships and helping clients resolve persistent structural challenges using advanced methodologies like MicroED. This commitment not only further enhances pharmaceutical development but also aids in protecting intellectual property in an ever-evolving market.

In conclusion, the publication of the crystal structure of Ritonavir Form IV marks a significant advancement in the field of pharmaceutical polymorphism. Improved Pharma continues to lead the way in addressing and solving complex structural problems, paving the future of drug development and ensuring the stability and efficacy of essential medications.

About Improved Pharma

Improved Pharma is a consulting and research company focusing on improving methods, formulations, and processes in the pharmaceutical industry. With services that include solid-state form studies, formulation design, and advanced analytical testing, the company plays a pivotal role in the safe development of drugs. Founded in 2006 by industry experts Stephen and Sarah Byrn, Improved Pharma has been instrumental in advancing pharmaceutical science.